Quick Answer
For patients who have plateaued at 1.0mg, the answer is usually yes. The dose-response curve shows additional weight loss at higher doses, and many patients who stalled at 1.0mg see progress resume at 1.7mg. The side effects during the 1 to 2 week adjustment are temporary, and the long-term side effect burden at 1.7mg is only marginally greater than at 1.0mg. For patients still losing weight at 1.0mg with good tolerance, the case for increasing is weaker. FormBlends evaluates each patient's trajectory individually rather than automatically escalating.
Medical Disclaimer: This article is for informational purposes only. Dose adjustments should always be made under medical supervision based on your individual clinical situation.
The Dose-Response Curve
Semaglutide's weight loss follows a pattern of diminishing returns at higher doses. The pooled STEP 1-3 analysis (Wharton et al., Diabetes Obesity Metabolism 2022) showed that the greatest marginal weight loss comes from the initial therapeutic doses (0.5mg to 1.0mg), with progressively smaller incremental gains at each higher dose level.
This does not mean higher doses are pointless. It means each additional dose step buys less additional weight loss while adding proportional side effects. The question at 1.7mg is whether the incremental benefit justifies the incremental cost. For many patients who have plateaued, the answer is clearly yes because any resumed weight loss is better than a stall.
FormBlends uses weight loss trajectory data rather than arbitrary protocols to guide dose decisions. A patient losing 1.5 pounds per week at 1.0mg has a different calculus than one who has been stuck at the same weight for 6 weeks.
When Increasing Makes Sense
Plateau confirmed: Weight loss has stalled for 4 to 6 consecutive weeks despite good adherence to dietary and activity recommendations. This is the clearest indication for a dose increase.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Significant weight remaining: Patients with 30+ pounds still to lose often benefit from higher doses that produce stronger appetite suppression and greater caloric deficit. The risk-benefit ratio favors dose escalation when there is substantial health benefit to be gained from further weight loss.
Standard protocol adherence: If you and your provider have decided to follow the full Wegovy titration to 2.4mg, 1.7mg is a required stop on the way. In this case, the question is not whether to increase but how to manage the transition well. For transition strategies, see our 1.7mg approaching max article.
When Staying Makes Sense
Active weight loss continuing: If you are still losing 0.5% or more of body weight per month at 1.0mg, there is no urgency to increase. The weight loss may slow eventually, but addressing that when it happens (rather than preemptively) avoids unnecessary side effects.
Side effects already challenging: If constipation, fatigue, or reduced quality of life at 1.0mg is already at the edge of tolerable, adding a higher dose will likely push past that edge. Sometimes a lower dose with acceptable side effects produces better long-term outcomes than a higher dose that leads to discontinuation.
Near goal weight: Patients within 10 to 15 pounds of their goal may not need the additional pharmaceutical push. At this stage, fine-tuning diet and exercise can close the remaining gap without the side effect burden of a higher dose. FormBlends helps patients transition from dose-dependent weight loss to habit-dependent weight maintenance as they approach their goals.
The Side Effect Trade-Off
| Factor | At 1.0mg | At 1.7mg |
|---|---|---|
| Appetite suppression | Strong for most | Very strong; some patients struggle to eat enough |
| Constipation management | Fiber + hydration usually sufficient | May need magnesium or MiraLAX addition |
| Nausea risk | Low at stable dose | Temporary during transition only |
| Quality of life impact | Minimal for most | Brief dip during adjustment, then similar to 1.0mg |
| Weight loss potential | Good for some, insufficient for others | Additional 5 to 10% may be achieved in non-responders at 1.0 |
The key insight from this comparison: after the 1 to 2 week adjustment period, the day-to-day experience at 1.7mg is not dramatically different from 1.0mg for most patients. The temporary discomfort of the transition is the main cost, and it resolves.
Is Your Plateau Real?
Before increasing your dose, FormBlends checks whether the weight plateau is genuine or a false alarm. Weight fluctuates naturally due to water retention, menstrual cycles, sodium intake, and exercise-related inflammation. A true plateau requires 4 to 6 weeks of flat weight trend, not only a few days or a single week.
Other factors to evaluate: Has dietary adherence drifted? Has physical activity decreased? Are there new medications that could affect weight? Is there an underlying hormonal issue (thyroid, cortisol)? FormBlends reviews these factors systematically because a dose increase will not overcome a non-pharmacological cause of stalling. For a detailed plateau assessment, see our when even max dose is not enough article.
The Community Debate
r/Semaglutide: "1.0 vs 1.7: is the extra side effects worth it?"
52 upvotes, 47 comments
A patient at 1.0mg for 4 months with slowing weight loss asked whether increasing was worthwhile. The thread produced strong opinions on both sides. Those who increased reported that the adjustment was rough for a week but worth it for restarted weight loss. Those who stayed at 1.0mg argued that lifestyle adjustments could accomplish the same thing without additional medication. The consensus leaned toward increasing if the plateau was confirmed and goals were not yet met.
Top comment: "Went to 1.7 after a 2 month plateau at 1.0. Lost another 18 pounds. The first week was miserable but it was a week. The extra weight loss was months."
r/Semaglutide: "Went back to 1.0 after trying 1.7"
29 upvotes, 22 comments
A patient tried 1.7mg for 3 weeks and decided to return to 1.0mg. Their reasoning: the constipation became difficult to manage, they had almost no appetite (eating under 800 calories most days), and the additional weight loss was modest. They preferred the quality of life at 1.0mg. This thread highlighted that dose optimization is personal, and higher is not always better for every individual.
Top comment: "The best dose is the one you can sustain long-term. If 1.0 keeps you on the medication and 1.7 makes you want to quit, 1.0 wins."
Clinical gap: Patient-centered outcomes comparing quality of life at different semaglutide dose levels are largely absent from the published literature. Weight loss and adverse event rates are reported, but systematic assessment of patient satisfaction, daily functioning, and overall well-being at each dose would inform more nuanced prescribing decisions.
Trying 1.7mg and Going Back
One underappreciated option is trying 1.7mg with the explicit understanding that returning to 1.0mg is acceptable. This removes the pressure of making a permanent commitment to a higher dose. If the side effects are manageable and weight loss resumes, great. If not, stepping back down is straightforward.
FormBlends frames dose increases this way because it reduces anxiety. Patients who view each increase as a trial rather than a one-way escalation are more willing to try higher doses and more honest about reporting when the side effects are not tolerable. This leads to better dose optimization over time.
Frequently Asked Questions
How much more weight will I lose at 1.7mg vs 1.0mg?
Varies individually. Many patients who plateau at 1.0mg see resumed weight loss of 0.5 to 1.5 pounds per week at 1.7mg. The dose-response curve shows additional benefit but with diminishing returns.
When should I not increase to 1.7mg?
If you are still losing weight at 1.0mg, if side effects are already borderline tolerable, if you are near your goal weight, or if you have GI conditions that worsen with further gastric emptying delay.
What does the dose-response curve look like?
Greatest marginal benefit from 0 to 1.0mg, progressively smaller gains at each higher dose. Each increase offers less additional weight loss while potentially adding more side effects.
Can I try 1.7mg and go back?
Yes. Dose reduction is safe and does not require re-titrating from 0.25mg. Many patients try higher doses and return to where they felt best.
Is the weight loss plateau at 1.0mg permanent?
Not necessarily. Evaluate dietary adherence, exercise, fluid retention, and other factors before assuming a dose increase is needed. True plateaus lasting 4 to 6 weeks may benefit from escalation.
Do additional side effects at 1.7mg resolve?
Most do. Nausea resolves in 1 to 2 weeks. Fatigue resolves as the body adapts. Constipation may persist slightly worse than at 1.0mg. The long-term burden is only marginally greater.